Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part Phase I Randomized Double Blind (Sponsor Open) Placebo Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Target Engagement and Potential for Efficacy of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Volunteers and Participants With Osteoarthritis of the Knee

Next Previous
Trial Profile

A Two-part Phase I Randomized Double Blind (Sponsor Open) Placebo Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Target Engagement and Potential for Efficacy of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Volunteers and Participants With Osteoarthritis of the Knee

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK-3858279 (Primary) ; GSK-3858279 (Primary)
  • Indications Pain
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 24 Sep 2019 Planned End Date changed from 27 Nov 2019 to 22 Feb 2021.
    • 24 Sep 2019 Planned primary completion date changed from 27 Nov 2019 to 22 Feb 2021.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top